National Cancer Institute; Notice of Meeting, 24166-24167 [2019-10944]

Download as PDF khammond on DSKBBV9HB2PROD with NOTICES 24166 Federal Register / Vol. 84, No. 101 / Friday, May 24, 2019 / Notices ‘‘CSC × 24 hrs’’ to represent Skp2 protein expression in CTCL Patients ➢ Six band images from Figure 5B in a paper published in Biochemistry 1 to represent Actin protein expression in eight (8) CTCL Patients, one (1) T– ALL Patient, and two (2) normal subjects in Figure 1 of JCI 2011 and Figure 3 (bottom panel) in R01 CA122737–01A2 • In Figure 8B (bottom part) in JCI 2011, also included as Figure 9 in R01 CA122737–01A2 and Slide 29 in the CREST Presentation, respondent falsely reused b-actin, Laminin B, alphatubulin, GFP-Pro-IL–16 and HSC70 band images of ‘‘Knockdown of HSC70 in Jurkat cells and Hut78 cells’’ as from Normal Human Patient and Normal Subject T-cells. • In Figure 14A in R01 CA122737– 01A2, respondent falsely reused GFPPro-IL–16 band images of ‘‘Knockdown of HSC70 in Jurkat cells’’ as AKT and phospho-AKT expression and the nuclear Pro-IL–16 band images from Figure 5B in Biochemistry 2002 as FOXO1 protein expression in human Tcells stimulated with IL–16. • In Figure 14B in R01 CA122737– 01A1 and R01 CA122737–01A2, respondent falsely reused band images from Figure 5B in Biochemistry 2002 that represents Anti-pro IL6 and AntiTubulin to represent FOXO1 protein expression in human T-cells. • In Figure 9 in JCI 2011, respondent falsely reused band images representing CD26–T cells of CTCL Patient to also represent normal human subject control for CD26+ and control for CD26–T cells in the same figure. • In Figure 5 in R01 CA122737–01A1, also included as Figure 4 in R01 CA122737–01A2, respondent reused and falsely relabeled band images within the same figure to represent different experimental conditions. Respondent intentionally, knowingly, and recklessly falsified and/or fabricated Western blot data for siRNA knockdown of Heat shock cognate 71 kDa protein (HSC70) in Jurkat cells purportedly with two different siRNA constructs, by reusing and relabeling ten (10) band images from experiments on Hut78 cells and a failed experiment in Jurkat cells, and included them in four (4) figures in one manuscript, one published paper, one grant application, and one presentation. Specifically, respondent reused band images of an unpublished Western blot figure, by: 1 Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry 2002;41:14306–14312 (hereafter referred to as ‘‘Biochemistry 2002’’). VerDate Sep<11>2014 18:10 May 23, 2019 Jkt 247001 • Reusing results of a single HSC70 siRNA knockdown on Hut78 cells and relabeling them to represent data from Jurkat cells in Figure 6 in the first submission of the JCI manuscript, Figure 6 in JCI 2011, and Figure 10 in R01 CA122737–01A2 (also included as Slide 27 in the CREST Presentation) • reusing results for a second siRNA construct that failed to knockdown HSC70 in Jurkat cells and relabeling them as from control samples in Figure 6 in JCI 2011 Dr. Cruikshank entered into a Voluntary Exclusion Agreement (Agreement) and voluntarily agreed for a period of five (5) years, beginning on May 13, 2019: (1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); and (2) to exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Wanda K. Jones, Interim Director, Office of Research Integrity. [FR Doc. 2019–10874 Filed 5–23–19; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, June 10, 2018, 8:30 a.m. to June 11, 2018, 12:00 p.m., National Cancer Institute Shady Grove Campus, Rockville, MD 20850 which was published in the Federal Register on February 11, 2019, 84 FR 3312. This meeting notice is amended to add two subcommittee meetings on Sunday, June 9, 2019. The National Cancer Advisory Board (NCAB) Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities will meet on June 9, 2019 from 5:30 p.m. to 7:00 p.m. and the NCAB Subcommittee on Planning and Budget will meet on June 9, 2019 from 7:30 p.m. to 9:00 p.m. at PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 the Gaithersburg Marriott Washingtonian Center, 9751 Washington Boulevard, Room—To Be Determined, Gaithersburg, MD 20878. This meeting notice is also amended to change the meeting from a two-day to a one-day meeting, correct the year, and change the closed session agenda. The joint meeting of the NCAB and NCI Board of Scientific Advisors will now be held on June 10, 2019 with the open session from 8:30 a.m. to 4:45 p.m. and the closed session from 5:00 p.m. to 6:00 p.m. The closed session agenda is corrected to be the Review of NCAB grant applications. The meeting is partially Closed to the public. Dated: May 21, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–10943 Filed 5–23–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be held as a teleconference only and is open to the public to dial-in for participation. Individuals who plan to dial-in to the meeting and need special assistance or other reasonable accommodations in order to do so, should notify the Contact Person listed below in advance of the meeting. Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee; Translational Research Strategy Subcommittee (TRSS). Date: June 19, 2019, Time: 10:00 a.m. to 11:00 a.m. Agenda: Review the Glioblastoma (GBM) Working Group Report. Place: National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Telephone Conference Call), Phone: 240–276–6500, Conference Code: 1102766460, Passcode: 6460. Contact Person: Peter Ujhazy, MD, Ph.D., Deputy Associate Director, Translational Research Program, Division of Cancer Treatment and Diagnosis, National Institutes of Health, National Cancer Institute, 9609 Medical Center Drive, Room 3W106, Rockville, MD 20850, 240–276–5681, ujhazyp@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on E:\FR\FM\24MYN1.SGM 24MYN1 Federal Register / Vol. 84, No. 101 / Friday, May 24, 2019 / Notices this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: May 21, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–10944 Filed 5–23–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Minority Health and Health Disparities; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute on Minority Health and Health Disparities Special Emphasis Panel, which was published in the Federal Register on May 10, 2019, 91FR20644. This Federal Register Notice is being amended to correct the Contact Person’s phone number and email address from (301) 451–2432, ismonddr@mail.nih.gov to (301) 451–9536, mlaudesharp@ nih.gov. The meeting is closed to the public. Dated: May 21, 2019. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–10947 Filed 5–23–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT khammond on DSKBBV9HB2PROD with NOTICES [Docket No. FR–7014–N–07] 60-Day Notice of Proposed Information Collection; Comprehensive Transactional Forms Supporting FHA’s Section 242 Mortgage Insurance Program for Hospitals Office of the Assistant Secretary for Housing, HUD. AGENCY: VerDate Sep<11>2014 18:10 May 23, 2019 Jkt 247001 ACTION: Notice. HUD is seeking approval from the Office of Management and Budget (OMB) for the information collection described below. In accordance with the Paperwork Reduction Act, HUD is requesting comment from all interested parties on the proposed collection of information. The purpose of this notice is to allow for 60 days of public comment. DATES: Comments Due Date: July 23, 2019. ADDRESSES: Interested persons are invited to submit comments regarding this notice. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Collette Pollard, Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 7th Street SW, Room 4176, Washington, DC 20410– 5000; telephone (202) 402–3400 or email at Colette.Pollard@hud.gov for information. Persons with hearing or speech impairments may access this number through TTY by calling the tollfree Federal Relay Service at (800) 877– 8339. Facsimile (fax) comments are not acceptable. FOR FURTHER INFORMATION CONTACT: Paul A Giaudrone, Office of Healthcare Programs, Office of Hospital Facilities, Department of Housing and Urban Development, 451 7th Street SW, Washington, DC 20410; telephone (202) 708–0599 (this is not a toll free number). Persons with hearing or speech impairments may access this number through TTY by calling the toll-free Federal Relay Service at (800) 877–8339. Facsimile (fax) comments are not acceptable. SUPPLEMENTARY INFORMATION: This notice informs the public that HUD is seeking approval from OMB for the information collection described in Section A. SUMMARY: A. Overview of Information Collection Title of Information Collection: Comprehensive Transactional Forms Supporting FHA’s Section 242 Mortgage Insurance Program for Hospitals. OMB Approval Number: 2502–0602. Type of Request: Revision of a currently approved collection. Form Numbers: HUD–91070–OHF, HUD–91071–OHF, HUD–91073–OHF, HUD–91111–OHF, HUD–91725–OHF, HUD–92013–OHF, HUD–92023–OHF, HUD–92070–OHF, HUD–92080–OHF, HUD–92117–OHF, HUD–92205–OHF, HUD–92223–OHF, HUD–92266–OHF, HUD–92322–OHF, HUD–92330–OHF, HUD–92330A–OHF, HUD–92403–OHF, PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 24167 HUD–92403A–OHF, HUD–92415–OHF, HUD–92422–OHF, HUD–92434–OHF, HUD–92441–OHF, HUD–92442–OHF, HUD–92448–OHF, HUD–92452A–OHF, HUD–92452–OHF, HUD–92455–OHF, HUD–92456–OHF, HUD–92464–OHF, HUD–92466–OHF, HUD–92476–OHF, HUD–92476A–OHF, HUD–92476B– OHF, HUD–92479–OHF, HUD–92554– OHF, HUD–92576–OHF, HUD–93305– OHF, HUD–94000–OHF, HUD–94001– OHF, HUD–94128–OHF. Description of the Need for the Information and Proposed Use This collection of information is required specifically for the application and administration of the Department of Housing and Urban Development, Federal Housing Administration Section 242 Hospital Mortgage Insurance Program pursuant to 24 CFR 242, 241, 223(f), and 223(a)(7). The collection is a comprehensive set of HUD documents that are critically needed for processing applications and loan endorsements for FHA mortgage insurance under the Section 242 Hospital Mortgage Insurance Program, for ongoing asset management of such facilities, and other information related to these facilities for loan modifications, construction projects, and physical and environmental reviews. This information is requested and is used by the Office of Healthcare Facilities (OHF) and Office of Architecture and Engineering (OAE) within FHA’s Office of Healthcare Programs (OHP). The purpose for which the information is being collected by HUD is to review Section 242 applications to determine the eligibility of applicant hospitals for FHA mortgage insurance, underwrite insured hospital loans, ensure that the collateral securing each loan is adequate, capture administrative data, process initial/final endorsement, and manage FHA’s hospital portfolio. Additional information related to loan modifications, construction projects, and physical and environmental reviews is collected if applicable. The information being collected consists of various HUD forms that program participants complete with project specifications, technical descriptions, details, and/or signatures that are utilized by HUD during various stages of the application, underwriting, commitment, closing, and asset management processes involved with the administration of FHA’s Section 242 mortgage insurance program. The information is used by HUD staff for internal review of applications to determine if projects qualify for Section 242 hospital mortgage insurance and to manage and monitor the application, E:\FR\FM\24MYN1.SGM 24MYN1

Agencies

[Federal Register Volume 84, Number 101 (Friday, May 24, 2019)]
[Notices]
[Pages 24166-24167]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10944]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be held as a teleconference only and is open to 
the public to dial-in for participation. Individuals who plan to dial-
in to the meeting and need special assistance or other reasonable 
accommodations in order to do so, should notify the Contact Person 
listed below in advance of the meeting.

    Name of Committee: National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee; Translational Research 
Strategy Subcommittee (TRSS).
    Date: June 19, 2019,
    Time: 10:00 a.m. to 11:00 a.m.
    Agenda: Review the Glioblastoma (GBM) Working Group Report.
    Place: National Cancer Institute Shady Grove, Shady Grove, 9609 
Medical Center Drive, Rockville, MD 20850 (Telephone Conference 
Call), Phone: 240-276-6500, Conference Code: 1102766460, Passcode: 
6460.
    Contact Person: Peter Ujhazy, MD, Ph.D., Deputy Associate 
Director, Translational Research Program, Division of Cancer 
Treatment and Diagnosis, National Institutes of Health, National 
Cancer Institute, 9609 Medical Center Drive, Room 3W106, Rockville, 
MD 20850, 240-276-5681, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on

[[Page 24167]]

this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: May 21, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-10944 Filed 5-23-19; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.